Stemline Therapeutics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Stemline Therapeutics (STML) Tops Q3 EPS by 6c
November 6, 2015 8:04 AM ESTStemline Therapeutics (NASDAQ: STML) reported Q3 EPS of ($0.53), $0.06 better than the analyst estimate of ($0.59).
For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.
... More